Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.65 |
| ▸ | NPC1 | O15118 | 3/20 | 0.65 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.65 |
| ▸ | APP | P05067 | 3/20 | 0.59 |
| ▸ | LDHA | P00338 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | CLK1 | P49759 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | GPR183 | P32249 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.47 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14538092 | 0.86 | DYRK1A (0.65) | RAB9ANPC1DYRK1ACYP2C19CYP1A2 | |
| SCHEMBL30470604 | 0.86 | DYRK1A (0.65) | RAB9ANPC1DYRK1ACYP2C19CYP1A2 | |
| Hydrochloric Acid SCHEMBL28370948 | 0.84 | DYRK1A (0.63) | RAB9ANPC1DYRK1ACYP2C19CYP1A2 | |
| SCHEMBL28878457 | 0.83 | RAB9A (0.61) | RAB9ANPC1DYRK1ACYP2C19CYP1A2 | |
| SCHEMBL29974198 | 0.83 | RAB9A (0.61) | RAB9ANPC1DYRK1ACYP2C19CYP1A2 | |
| SCHEMBL2076551 | 0.82 | RAB9A (0.65) | RAB9ANPC1DYRK1ACYP2C19CYP1A2 | |
| SCHEMBL1621946 | 0.81 | RAB9A (0.60) | RAB9ANPC1DYRK1ACYP2C19CYP1A2 | |
| SCHEMBL17680377 | 0.81 | RAB9A (0.60) | RAB9ANPC1DYRK1ACYP2C19CYP1A2 | |
| SCHEMBL31286730 | 0.81 | RAB9A (0.56) | RAB9ANPC1DYRK1ACYP2C19CYP1A2 | |
| SCHEMBL13151088 | 0.80 | NPC1 (0.64) | RAB9ANPC1DYRK1AAPPLDHA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3735411-B1 | 1,3,4,5-TETRAHYDRO-2H-PYRIDO[4,3-B]INDOLE DERIVATIVES FOR THE TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES LIKE ALZHEIMER`S DISEASE | AC IMMUNE SA (CH) | 2024-07-10 | — | — | EP | disclosed |
| US-11814378-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | AC IMMUNE SA (CH) | 2023-11-14 | — | — | US | disclosed |
| US-11814378-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | AC IMMUNE SA (CH) | 2023-11-14 | — | — | US | disclosed |
| US-20230255976-A1 | Novel Compounds for the Treatment, Alleviation or Prevention of Disorders Associated with Tau Aggregates | AC IMMUNE SA (CH) | 2023-08-17 | — | — | US | disclosed |
| US-20230255976-A1 | Novel Compounds for the Treatment, Alleviation or Prevention of Disorders Associated with Tau Aggregates | AC IMMUNE SA (CH) | 2023-08-17 | — | — | US | disclosed |
| US-11684625-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with tau aggregates | AC IMMUNE SA (CH) | 2023-06-27 | — | — | US | disclosed |
| US-11684625-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with tau aggregates | AC IMMUNE SA (CH) | 2023-06-27 | — | — | US | disclosed |
| CN-110914238-B | Compounds as antibiotics | 安塔比奥公司 | 2023-06-20 | — | — | CN | disclosed |
| US-11242346-B2 | Mechanistic target of rapamycin signaling pathway inhibitors and therapeutic applications thereof | SUZHOU KINTOR PHARMACEUTICALS, INC. (CN) | 2022-02-08 | — | — | US | disclosed |
| US-20200181147-A1 | MECHANISTIC TARGET OF RAPAMYCIN SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF | SUZHOU KINTOR PHARMACEUTICALS, INC. (CN) | 2020-06-11 | — | — | US | disclosed |
| EP-2183232-B1 | PI3 KINASE MODULATORS AND METHODS OF USE | AMGEN INC (US) | 2013-03-06 | — | — | EP | disclosed |
| US-20110124641-A1 | BENZOTHIAZOLE KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC | 2011-05-26 | — | — | US | disclosed |
| US-20110124641-A1 | BENZOTHIAZOLE KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC | 2011-05-26 | — | — | US | disclosed |
| US-20110124641-A1 | BENZOTHIAZOLE KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC | 2011-05-26 | — | — | US | disclosed |
| US-7928140-B2 | Benzothiazole PI3 kinase modulators for cancer treatment | AMGEN INC. (US) | 2011-04-19 | — | — | US | disclosed |
| EP-2183232-A2 | PI3 KINASE MODULATORS AND METHODS OF USE | Amgen, Inc (US) | 2010-05-12 | — | — | EP | disclosed |
| WO-2009114874-A2 | BENZOTHIAZOLE KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE, INC. (US) | 2009-09-17 | — | — | WO | disclosed |
| WO-2009114874-A2 | BENZOTHIAZOLE KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE, INC. (US) | 2009-09-17 | — | — | WO | disclosed |
| US-20090054405-A1 | PI3 kinase modulators and methods of use | AMGEN INC. (US) | 2009-02-26 | — | — | US | disclosed |
| WO-2009017822-A2 | PI3 KINASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054405-A1 | PI3 kinase modulators and methods of use | PIK3CA, PIK3C2A, PIK3C2B | RAB9A 971/4885NPC1 2720/4885DYRK1A 841/4885 |
| US-20230255976-A1 | Novel Compounds for the Treatment, Alleviation or Prevention of Disorders Associated with Tau Aggregates | MAPT, MAP1LC3A, MAP1LC3B | RAB9A 1905/4885NPC1 290/4885DYRK1A 3415/4885 |
| US-11242346-B2 | Mechanistic target of rapamycin signaling pathway inhibitors and therapeutic applications thereof | MTOR, RPTOR, RICTOR | RAB9A 764/4885NPC1 1615/4885DYRK1A 3887/4885 |
| US-11684625-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with tau aggregates | MAPT, PSEN2, PSEN1 | RAB9A 2191/4885NPC1 144/4885DYRK1A 4167/4885 |
| US-20200181147-A1 | MECHANISTIC TARGET OF RAPAMYCIN SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF | MTOR, RPTOR, RICTOR | RAB9A 764/4885NPC1 1615/4885DYRK1A 3887/4885 |
| US-20110124641-A1 | BENZOTHIAZOLE KINASE INHIBITORS AND METHODS OF USE | MTOR, PDPK1, PIKFYVE | RAB9A 2991/4885NPC1 1321/4885DYRK1A 623/4885 |
| US-11814378-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | MAPT, MAP1LC3A, TUBB3 | RAB9A 2189/4885NPC1 325/4885DYRK1A 3607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.